drugset / Trial / NCT03489239

Entecavir to TAF Switch

NCT03489239

Phase 3 Active not recruiting 27 enrolled Thomas Jefferson University Gilead Sciences · collab
NaSingle-groupOpen-labelOther

Summary

A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B

Timeline

Start
2017-11-16
Primary completion
2020-08-15
Completion
2020-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject tenofovir alafenamide Small molecule 25 mg